LLY is the best choice for growth given its dominant position in the weight loss/diabetes market and strong pipeline, though it lacks a high dividend yield.

moving on to the second purchase, we actually have to stay within the pharmaceutical sector for another name that has achieved, if you believe it, an even greater rise. It's kind of crazy.

This name is the recently trillion-dollar pharmaceutical giant, Eli Lilly, whose trading symbol is “LLY”, in which Saudi Arabia has nearly doubled its investments this quarter, pumping about $28 million into this center.

Now, if you want to understand why financial institutions are willing to chase this stock near its record highs, as are hedge funds and other institutional buyers, look no further than the massive explosion in the weight loss and diabetes treatment market .

Lilly is not only participating in this trend, but practically dominating it at this stage with its successful injectable drugs, Mongaro and Zybound, along with its new Orforglibrone pills, a new daily weight loss pill that has far fewer restrictions and is likely to see increased demand in the coming months and years.

In fact, it already accounts for what I believe is over 30 % of new oral obesity prescriptions in America. So, it's kind of crazy. Furthermore, they also have a more powerful drug in their final stages of development.

It is called "Retatrotide". This is, in fact, what is called a triple activator. This is because it targets three different hormones, rather than just one or two, for weight loss.

He is currently in the third phase of trials, but the results look very promising for them because he achieved an amazing 28% decrease in average body weight . I mean, this is practically equivalent to the results of obesity surgeries. This came only from medicine.

Analysts believe that this property alone could easily generate tens of billions in annual sales at its peak in the future. As a result of this and their future plans as well, analysts expect continued tremendous growth in revenues and profits, which undoubtedly puts the sector at the forefront in relation to their size .

Although the share price has skyrocketed with those figures, the valuation is not actually as crazy as you might think, given all the expansion in profits that helps balance that valuation .

In fact, like AbbVie, their PEG ratio is even lower than the industry average, if you can believe it.

As for me, the only thing that puts me off is that I like biotech companies and pharmaceutical giants to pay large dividends, like Pfizer, for example, which is not only cheaper in price and valuation , but also generates more than 6% as a dividend yield, while Eli Lilly generates less than 1%.

She is certainly not forgotten, nor is "Abfi" in this regard. At today's levels, and given the tremendous growth, I actually think Eli Lilly is the one I would give the edge to in our rankings over AbbVie.

So I will put it in second place even though I own AbbVie shares myself.

But again, the cost of investing in AbbVie for me is much lower than today's trading price, and that's why I own this stock , whereas with Eli Lilly , if I had to choose a stock at today's levels , I think I would choose Lilly because of what I see as its more explosive growth potential .

If you're looking for growth, I think Lily would be the best choice. But as a whole package, I think Apple might have a slight edge. maybe. The two are very similar. Tell me in the comments below which stock you would prefer to own if you had to choose one stock for your portfolio.

I think many of you might say Eli Lilly, which I would understand. But if I had to choose, I'd say Apple.